Brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to post earnings per share of ($0.63) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.84). Crispr Therapeutics reported earnings of ($0.62) per share during the same quarter last year, which suggests a negative year over year growth rate of 1.6%. The firm is expected to announce its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($2.89) per share for the current year, with EPS estimates ranging from ($3.16) to ($2.38). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.09) per share, with EPS estimates ranging from ($3.70) to ($1.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The business had revenue of $1.09 million during the quarter, compared to analyst estimates of $1.47 million.

Several research firms recently issued reports on CRSP. Zacks Investment Research raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Wednesday, May 23rd. ValuEngine raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. BidaskClub lowered shares of Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 5th. Chardan Capital lifted their price objective on shares of Crispr Therapeutics from $25.00 to $72.50 and gave the company a “buy” rating in a research note on Tuesday, May 15th. Finally, TheStreet lowered shares of Crispr Therapeutics from a “c” rating to a “d+” rating in a research note on Friday, May 11th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $65.90.

CRSP stock opened at $47.95 on Tuesday. Crispr Therapeutics has a 1 year low of $16.16 and a 1 year high of $73.90.

In other Crispr Therapeutics news, Director Kurt Von Emster sold 650,000 shares of the business’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $54.39, for a total transaction of $35,353,500.00. Following the completion of the transaction, the director now owns 5,629 shares of the company’s stock, valued at approximately $306,161.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Thursday, July 5th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the transaction, the director now directly owns 5,816 shares of the company’s stock, valued at approximately $360,592. The disclosure for this sale can be found here. In the last ninety days, insiders sold 754,236 shares of company stock valued at $41,731,001. 37.70% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. acquired a new position in Crispr Therapeutics during the 2nd quarter worth $116,000. First Mercantile Trust Co. acquired a new position in Crispr Therapeutics during the 2nd quarter worth $141,000. SeaCrest Wealth Management LLC lifted its position in Crispr Therapeutics by 202.9% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after acquiring an additional 1,826 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Crispr Therapeutics by 66.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock worth $166,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Private Advisor Group LLC acquired a new position in Crispr Therapeutics during the 2nd quarter worth $227,000. 37.65% of the stock is owned by hedge funds and other institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Recommended Story: Relative Strength Index

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.